HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1746-1596
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population ; volume:8 ; number:1 ; day:9 ; month:5 ; year:2013 ; pages:1-7 ; date:12.2013
Diagnostic pathology ; 8, Heft 1 (9.5.2013), 1-7, 12.2013
- Urheber
-
Shan, Ling
- Beteiligte Personen und Organisationen
-
Ying, Jianming
Lu, Ning
SpringerLink (Online service)
- DOI
-
10.1186/1746-1596-8-76
- URN
-
urn:nbn:de:1111-2016080742924
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shan, Ling
- Ying, Jianming
- Lu, Ning
- SpringerLink (Online service)
Ähnliche Objekte (12)
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma : Past, present and future
Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma : Past, present and future
Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma : Past, present and future
Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma